Active surveillance for favorable-risk prostate cancer: Background, patient selection, triggers for intervention, and outcomes

Current Urology Reports

Volumn 13, Issue 2, 2012, Pages 153-159

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Conservative management; Overdiagnosis; Overtreatment; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; WATCHFUL WAITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERVENTION STUDIES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PRECIPITATING FACTORS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS; WATCHFUL WAITING;

EID: 84860717371     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0242-4     Document Type: Review

References (40)

1. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-13.
2. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040-52.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
4. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Gotebörg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-32.
5. Chou R, Croswell JM, Dana T, et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/uspstf12/ prostate/prostateart. htm. Accessed January 2012.
6. Greene KK, Albertsen PC, Babaian RJ, et al. PSA best practice statement: 2009 update. J Urol. 2009;182:2232-41.
7. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28 (1):126-31.
8. Eggener S, Scardino P, Walsh P, et al. 20 year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;85 (3):869-75.
9. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989;141(5):1091-4. (Pubitemid 19124204)
10. Wolters T, Roobol M, Schröder F, van der Kwast T. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol. 2011;185:121-5.
11. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-83.
12. RP vs WW in Early PCa Bill-Axelson A, Holmberg L NEJM 364;18, May 5 2011
13. Klotz L, Thompson I. Early prostate cancer-treat or watch? N Engl J Med. 2011;365(6):569.
14. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277(6):467-71. (Pubitemid 27074330)
15. Van As NJ, Parker C. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007;13(5):289-94.
16. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178(6):2359-65. (Pubitemid 350052183)
17. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2008 Sep 17
18. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2007 Sep 10; [Epub ahead of print]
19. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol. 2007;51 (5):1244-50.
20. Khatami A, Hugusson PSA DT and surveillance: Int J Cancer 2006; 120, 170-174.
21. van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, et al. Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer. 2010;116(5):1281-90.
22. van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, et al. Bangma CHShort-term outcomes of the prospective multicentre 'Prostate Cancer Research International: active surveillance' study. BJU Int. 2010;105(7):956-62.
23. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55(1):1-8.
24. Oliveira IS, Pontes-Junior J, Abe DK, Crippa A, Dall'oglio MF, Nesralah AJ, et al. Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy. Int Braz J Urol. 2010;36(3):292-9.
25. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, et al.; SEARCH Database Study Group. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010 Apr 13.
26. Raventós CX, Orsola A, de Torres I, Cecchini L, Trilla E, Planas J, et al. Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores. Urol Int. 2010;84(2):153-8.
27. Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance- does the risk of misclassification vary according to biopsy criteria? J Urol. 2010;183(2):539-44.
28. Thaxton CS, Loeb S, Roehl KA, Kan D, Catalona WJ. Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology. 2010;75(2):414-8.
29. Smaldone MC, Cowan JE, Carroll PR, Davies BJ. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol. 2010;183(1):138-43.
30. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, et al. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extendedcore biopsies: an analysis of volume and zonal distribution of tumour foci.
31. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009;182(5):2274-8.
32. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology. 2010 May 20. [Epub ahead of print]
33. Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol. 2010;184(5):1942-6.
34. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810-6.
35. Vickers A. Systematic review of pretreatment PSA velocity and doubling time As PCA predictors. J Clin Oncol. 2008;27:398-403.
36. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral lowrisk prostate cancer. Prostate Cancer Prostatic Dis 14:232-237
37. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol. 2009 Sep 7
38. Fütterer JJ, Barentsz J, Heijmijnk ST. Imaging modalities for prostate cancer. Expert Rev Anticancer Ther. 2009;9(7):923-37.
39. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol. 2006;176(4 Pt 1):1392-7.
40. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol. 2009;24(5):661-6.